vs
Side-by-side financial comparison of HSBC HOLDINGS PLC (HSBC) and Pfizer (PFE). Click either name above to swap in a different company.
HSBC HOLDINGS PLC is the larger business by last-quarter revenue ($28.6B vs $17.6B, roughly 1.6× Pfizer). HSBC HOLDINGS PLC runs the higher net margin — 25.7% vs -9.4%, a 35.1% gap on every dollar of revenue. HSBC HOLDINGS PLC produced more free cash flow last quarter ($64.0B vs $4.5B).
HSBC Holdings plc is a British universal bank and financial services group headquartered in London, England, with historical and business links to East Asia and a multinational footprint. It is the largest Europe-based bank by total assets, ahead of BNP Paribas, with US$3.098 trillion as of September 2024. This also puts it as the 7th largest bank in the world by total assets behind Bank of America, and the 3rd largest non-state owned bank in the world.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer (1824–1906) and Charles F. Erhart (1821–1891), Pfizer is one of the oldest pharmaceutical companies in North America.
HSBC vs PFE — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $28.6B | $17.6B |
| Net Profit | $7.3B | $-1.6B |
| Gross Margin | — | 70.0% |
| Operating Margin | 33.1% | -9.4% |
| Net Margin | 25.7% | -9.4% |
| Revenue YoY | — | -1.2% |
| Net Profit YoY | — | -501.7% |
| EPS (diluted) | $0.36 | $-0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $17.6B | ||
| Q3 25 | — | $16.7B | ||
| Q2 25 | — | $14.7B | ||
| Q1 25 | $28.6B | $13.7B | ||
| Q4 24 | — | $17.8B | ||
| Q3 24 | — | $17.7B | ||
| Q2 24 | — | $13.3B | ||
| Q1 24 | — | $14.9B |
| Q4 25 | — | $-1.6B | ||
| Q3 25 | — | $3.5B | ||
| Q2 25 | — | $2.9B | ||
| Q1 25 | $7.3B | $3.0B | ||
| Q4 24 | — | $410.0M | ||
| Q3 24 | — | $4.5B | ||
| Q2 24 | — | $41.0M | ||
| Q1 24 | — | $3.1B |
| Q4 25 | — | 70.0% | ||
| Q3 25 | — | 74.9% | ||
| Q2 25 | — | 74.2% | ||
| Q1 25 | — | 79.3% | ||
| Q4 24 | — | 66.7% | ||
| Q3 24 | — | 70.3% | ||
| Q2 24 | — | 75.2% | ||
| Q1 24 | — | 77.3% |
| Q4 25 | — | -9.4% | ||
| Q3 25 | — | 20.0% | ||
| Q2 25 | — | 20.8% | ||
| Q1 25 | 33.1% | 20.3% | ||
| Q4 24 | — | -0.1% | ||
| Q3 24 | — | 26.6% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | 23.0% |
| Q4 25 | — | -9.4% | ||
| Q3 25 | — | 21.3% | ||
| Q2 25 | — | 19.9% | ||
| Q1 25 | 25.7% | 21.6% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 25.2% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 20.9% |
| Q4 25 | — | $-0.29 | ||
| Q3 25 | — | $0.62 | ||
| Q2 25 | — | $0.51 | ||
| Q1 25 | $0.36 | $0.52 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | — | $0.78 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $434.9B | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $192.3B | $86.5B |
| Total Assets | $3017.0B | $208.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.6B | ||
| Q1 25 | $434.9B | $1.4B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $719.0M |
| Q4 25 | — | $86.5B | ||
| Q3 25 | — | $92.8B | ||
| Q2 25 | — | $88.7B | ||
| Q1 25 | $192.3B | $90.3B | ||
| Q4 24 | — | $88.2B | ||
| Q3 24 | — | $92.3B | ||
| Q2 24 | — | $87.7B | ||
| Q1 24 | — | $92.3B |
| Q4 25 | — | $208.2B | ||
| Q3 25 | — | $208.7B | ||
| Q2 25 | — | $206.1B | ||
| Q1 25 | $3017.0B | $208.0B | ||
| Q4 24 | — | $213.4B | ||
| Q3 24 | — | $219.5B | ||
| Q2 24 | — | $216.2B | ||
| Q1 24 | — | $221.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $65.3B | $5.3B |
| Free Cash FlowOCF − Capex | $64.0B | $4.5B |
| FCF MarginFCF / Revenue | 223.9% | 25.6% |
| Capex IntensityCapex / Revenue | 4.7% | 4.8% |
| Cash ConversionOCF / Net Profit | 8.90× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $9.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.3B | ||
| Q3 25 | — | $4.6B | ||
| Q2 25 | — | $-582.0M | ||
| Q1 25 | $65.3B | $2.3B | ||
| Q4 24 | — | $6.7B | ||
| Q3 24 | — | $6.7B | ||
| Q2 24 | — | $-1.8B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | — | $4.5B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | — | $-1.2B | ||
| Q1 25 | $64.0B | $1.8B | ||
| Q4 24 | — | $5.8B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | — | $-2.4B | ||
| Q1 24 | — | $386.0M |
| Q4 25 | — | 25.6% | ||
| Q3 25 | — | 24.0% | ||
| Q2 25 | — | -8.2% | ||
| Q1 25 | 223.9% | 12.9% | ||
| Q4 24 | — | 32.7% | ||
| Q3 24 | — | 34.3% | ||
| Q2 24 | — | -18.2% | ||
| Q1 24 | — | 2.6% |
| Q4 25 | — | 4.8% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | 4.7% | 4.1% | ||
| Q4 24 | — | 5.2% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 4.8% | ||
| Q1 24 | — | 4.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | -0.20× | ||
| Q1 25 | 8.90× | 0.79× | ||
| Q4 24 | — | 16.39× | ||
| Q3 24 | — | 1.50× | ||
| Q2 24 | — | -43.44× | ||
| Q1 24 | — | 0.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HSBC
Segment breakdown not available.
PFE
| U.S.Commercial Division | $9.0B | 51% |
| Specialty Care | $4.8B | 27% |
| Total Alliance Biopharmaceuticals | $2.6B | 15% |
| Royalty | $480.0M | 3% |
| Pfizer Centre One | $409.0M | 2% |
